Last A$0.14 AUD
Change Today 0.00 / 0.00%
Volume 373.4K
As of 12:10 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

regeneus ltd (RGS) Snapshot

Open
A$0.14
Previous Close
A$0.14
Day High
A$0.15
Day Low
A$0.14
52 Week High
11/26/13 - A$0.66
52 Week Low
10/7/14 - A$0.10
Market Cap
29.2M
Average Volume 10 Days
199.3K
EPS TTM
A$-0.05
Shares Outstanding
208.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGENEUS LTD (RGS)

Related News

No related news articles were found.

regeneus ltd (RGS) Related Businessweek News

No Related Businessweek News Found

regeneus ltd (RGS) Details

Regeneus Ltd, a regenerative medicine company, develops and commercializes stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions in Australia. The company provides HiQCell, an autologous adipose derived stem cell therapy for human osteoarthritis and other musculoskeletal conditions. It also offers animal health products comprising CryoShot, an allogeneic cell-based product for use as an intra-articular injection for osteoarthritis, an adjunct to joint surgery, and an intra-lesional injection for tendinopathy in canine and equine markets; and Kvax, an autologous therapeutic cancer vaccine. In addition, the company is developing a stem cell secretions cream for inflammatory skins conditions, such as acne, rosacea, and psoriasis; and Progenza, an allogeneic cell therapy treatment for human osteoarthritis. Regeneus Ltd was founded in 2007 and is headquartered in Pymble, Australia.

Founded in 2007

regeneus ltd (RGS) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: A$440.5K
Chief Scientific Officer and Executive Direct...
Total Annual Compensation: A$339.5K
Compensation as of Fiscal Year 2014.

regeneus ltd (RGS) Key Developments

Regeneus Ltd Announces Board and Management Changes

Regeneus Ltd. announced changes to its Board and senior management team consistent with its focus on increasing commercial and partnering activities for its regenerative medicine products, reducing costs and greater Board independence. After leading the company through a period of significant change and growth over the last 7 years, the company's founding CEO and major shareholder, Professor Graham Vesey, will step down as CEO and take up the position of Chief Scientific Officer, effective immediately. Dr. Vesey will remain on the Board as an executive director with an appropriately reduced remuneration package. John Martin, the Executive Chairman, will step down as Chairman and take on the role of CEO effective immediately, with a focus on taking actions necessary to increase commercial and partnering activities and reducing costs. Independent non-executive director, Dr. Roger Aston, has been appointed as Independent Chairman. Dr. Aston is one of Australia's experienced pharma and biotech industry executives with a strong track record in drug development and partnering. Dr. Aston will work closely with the new CEO in making sure that the market and all stakeholders have a clear understanding of the company's strategy and plans to build shareholder value over the next phase. The Board will look to appoint a new independent director with relevant healthcare and biotech experience. Non-executive director and co-founder, Dr. Ben Herbert, will step down from the Board with immediate effect. Dr Herbert played a key role as a co-founder of company in 2007 and has made a significant contribution since start-up as a founding non-executive director. The company announced the appointment of John Bird as its new Chief Financial and Operations Officer. John is an experienced finance and operations executive with over 25 years experience in senior finance and operations roles. John will provide important leadership in enabling the company to meet its operational and financial targets for the next 2 years including its quarterly cash burn target of $1.7 million pre any R&D rebate.

Regeneus Ltd Presents at 5th Annual Australian Microcap Investment Conference, Oct-21-2014 01:45 PM

Regeneus Ltd Presents at 5th Annual Australian Microcap Investment Conference, Oct-21-2014 01:45 PM. Venue: Sofitel Molbourne On collins, Arthur Streeton Auditorium, 25 Collins Street, Melbourne, VIC 3000, Australia. Speakers: John Dominic Martin, Executive Chairman, Member of Remuneration & Nominations Committee and Member of Audit & Risk Committee.

Regeneus Ltd Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 03:00 PM

Regeneus Ltd Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 03:00 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGS:AU A$0.14 AUD 0.00

RGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Orthocell Ltd A$0.46 AUD +0.035
View Industry Companies
 

Industry Analysis

RGS

Industry Average

Valuation RGS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.2x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENEUS LTD, please visit www.regeneus.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.